Language
English
Publication Date
10-1-2020
Journal
The Journal Of Clinical And Aesthetic Dermatology
PMID
33584954
PMCID
PMC7840091
PubMedCentral® Posted Date
10-1-2020
PubMedCentral® Full Text Version
Post-print
Abstract
A 64 year-old Caucasian male patient with a long history of ultraviolet light exposure and multiple actinic keratoses presented with a large, erythematous, and scaly plaque on his forehead. Biopsies revealed superficial basal cell carcinoma (sBCC). Because the patient wanted the shortest possible topical regimen, his sBCC was treated with two overnight ingenol mebutate (IM) 0.05% gel applications. He tolerated the local skin reaction (LSR) well, and at approximately six weeks post-treatment, biopsies showed no evidence of sBCC. The patient was happy with the cosmetic outcome and has remained free of clinical recurrence for 18 months. Although IM gel is only FDA approved for the treatment of actinic keratosis, it has also been used off-label to treat other epithelial lesions, including basal cell carcinoma (BCC), anogenital warts, and Bowen's disease. One clinical trial, multiple case series and case reports, and now this report, have demonstrated IM's utility in treating BCC. IM treatment is therefore a promising alternative to surgery for select BCC, with major advantages, including a short treatment duration and generally favorable cosmetic outcome.
Keywords
Superficial basal cell carcinoma, ingenol mebutate gel, topical treatment, nodular basal cell carcinoma, Bowen’s disease, squamous cell carcinoma in situ, anogenital warts, condylomata acuminata
Published Open-Access
yes
Recommended Citation
, "Superficial Basal Cell Carcinoma of the Face Successfully Treated with Ingenol Mebutate 005% Gel: Case Report and a Review of the Literature" (2020). Faculty, Staff and Students Publications. 485.
https://digitalcommons.library.tmc.edu/baylor_docs/485